Key Events This Week
3 Aug: Stock hits 52-week low at Rs.4.95 and also hits upper circuit
6 Aug: Price dips to Rs.5.04 amid continued selling pressure
7 Aug: New 52-week low of Rs.4.91 recorded despite intraday gains
3 August: Volatile Session with 52-Week Low and Upper Circuit Hit
On 3 August 2026, Vivimed Labs Ltd experienced a highly volatile trading day. The stock touched a fresh 52-week low of Rs.4.95, reflecting ongoing fundamental weaknesses and bearish sentiment. Despite this, the share price rebounded sharply during the session, hitting the upper circuit limit at Rs.5.33 intraday, before settling at Rs.5.15, a 1.38% gain on the day.
This unusual price action was accompanied by significant trading volume of approximately 2.32 lakh shares, indicating strong buying interest despite the company’s micro-cap status and recent negative outlook. The surge in delivery volumes by 269.55% compared to the five-day average suggests genuine investor participation rather than speculative trading.
However, the stock remained below all key moving averages, signalling that the broader downtrend was intact. The regulatory freeze triggered by the upper circuit capped further gains, leaving unfilled demand that could influence subsequent sessions.
4 August: Mild Decline Amid Market Consolidation
The following day, 4 August, Vivimed Labs Ltd’s stock price declined marginally by 0.39% to Rs.5.08, on relatively low volume of 3,861 shares. This modest fall occurred in a market environment where the Sensex also slipped by 0.14%, reflecting a cautious mood among investors. The stock’s inability to sustain the previous day’s gains highlighted persistent selling pressure and uncertainty about the company’s near-term prospects.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
5 August: Slight Recovery on Positive Market Momentum
On 5 August, the stock edged up by 0.79% to close at Rs.5.12, supported by a broader Sensex gain of 0.38%. Trading volume increased to 8,885 shares, indicating renewed interest. Despite this uptick, Vivimed Labs remained below its key moving averages, and the recovery was insufficient to reverse the prevailing bearish trend. The stock’s micro-cap status and weak fundamentals continued to weigh on investor confidence.
6 August: Renewed Selling Pressure Pushes Price Lower
The stock faced renewed selling pressure on 6 August, falling 1.56% to Rs.5.04. This decline came despite the Sensex advancing by 0.28%, underscoring the stock’s underperformance relative to the broader market. Volume was moderate at 4,777 shares. The persistent weakness reflected ongoing concerns about the company’s financial health and operational losses, which have dampened sentiment.
Holding Vivimed Labs Ltd from ? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
7 August: New 52-Week Low Despite Intraday Gains
Vivimed Labs Ltd’s stock fell to a fresh 52-week low of Rs.4.91 on 7 August, closing the day at Rs.5.06 after a 0.40% gain. This intraday volatility reflected a mixed technical picture, with the stock trading above its 5-day moving average but remaining below longer-term averages. The Sensex declined by 0.21% on the day, indicating a cautious market environment.
Financially, the company continues to face significant challenges, including a negative EBITDA of Rs.-154.63 crore, a high Debt to EBITDA ratio of -2.61 times, and an average Return on Equity of just 1.75%. Profitability has deteriorated sharply, with a 452% decline over the past year. These factors underpin the stock’s sustained weakness and the recent downgrade to a Strong Sell Mojo Grade with a score of 12.0.
Daily Price Comparison: Vivimed Labs Ltd vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-08-03 | Rs.5.10 | -1.35% | 36,985.17 | +0.82% |
| 2026-08-04 | Rs.5.08 | -0.39% | 36,933.47 | -0.14% |
| 2026-08-05 | Rs.5.12 | +0.79% | 37,074.66 | +0.38% |
| 2026-08-06 | Rs.5.04 | -1.56% | 37,177.57 | +0.28% |
| 2026-08-07 | Rs.5.06 | +0.40% | 37,099.57 | -0.21% |
Key Takeaways
Persistent Financial Weakness: The company’s negative EBITDA of Rs.-154.63 crore and high Debt to EBITDA ratio of -2.61 times highlight ongoing operational and financial stress. Profitability remains subdued with a 452% decline in profits over the past year and an average ROE of 1.75%.
Volatile Price Action: The week saw sharp intraday swings, including a 52-week low and an upper circuit hit on the same day, reflecting mixed investor sentiment and speculative trading activity amid weak fundamentals.
Underperformance vs Market: Vivimed Labs declined 2.13% over the week while the Sensex gained 1.13%, underscoring the stock’s relative weakness despite intermittent buying interest.
Technical Indicators Bearish: The stock remains below key moving averages and exhibits predominantly bearish technical signals, including a Strong Sell Mojo Grade of 12.0, indicating caution for investors.
Conclusion
Vivimed Labs Ltd’s performance over the week ending 7 August 2026 reflects a company grappling with significant financial and operational challenges. Despite occasional bursts of buying interest, including an upper circuit hit, the stock’s overall trajectory remains downward, driven by weak fundamentals and bearish technical indicators. The divergence from the broader market’s positive trend further emphasises the stock’s struggles. Investors should remain attentive to the company’s financial health and market developments as the stock continues to navigate a difficult environment.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
